Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
about
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@en
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@nl
type
label
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@en
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@nl
prefLabel
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@en
Enzalutamide and CXCR7 inhibit ...... istant prostate cancer models.
@nl
P2093
P2860
P50
P356
P1476
Enzalutamide and CXCR7 inhibit ...... sistant prostate cancer models
@en
P2093
Dimitrios Korentzelos
Guang Yang
Jianhua Yin
Jianxiang Wang
Penglie Zhang
Sanghee Park
Spyridon P Basourakos
Styliani Karanika
P2860
P304
P356
10.1002/IJC.31237
P577
2018-01-30T00:00:00Z